Related Experiment Video
Updated: Aug 17, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Effect of anticholesterol therapy on soluble ICAM-1 in chronic stroke patients with hyperlipidemia
Hitoshi Tomiyasu1, Kiyoko Ishikawa, Masahiro Yamamoto
1Department of Internal Medicine, Tokai University School of Medicine, Boseidai, Isehara, Kanagawa 259-1193, Japan.
Insights
Pravastatin significantly reduced soluble intercellular adhesion molecule-1 (sICAM-1) in hyperlipidemic cerebrovascular disease patients. This suggests pravastatin offers anti-atherosclerotic benefits beyond lipid reduction.
Area of Science:
- Cardiovascular Medicine
- Neuroscience
- Pharmacology
Background:
- Hyperlipidemia is a significant risk factor for cerebrovascular disease (CVD).
- Soluble intercellular adhesion molecule-1 (sICAM-1) plays a role in atherogenesis and may be elevated in CVD patients.
- Understanding the impact of lipid-lowering therapies on sICAM-1 is crucial for managing CVD.
Purpose of the Study:
- To investigate the effects of pravastatin, bezafibrate, and diet therapy on serum lipids and sICAM-1 levels.
- To determine if lipid-lowering interventions impact sICAM-1 in chronic hyperlipidemic CVD patients.
Main Methods:
- A study involving 36 hyperlipidemic CVD patients (cerebral infarction or hemorrhage).
- Patients were divided into three groups: pravastatin (P), bezafibrate (B), and diet (D) therapy.
- Serum levels of total cholesterol (TC), LDL-C, triglyceride (TG), HDL-C, and sICAM-1 were measured before and after treatment.
Main Results:
- Pravastatin (Group P) significantly decreased TC, LDL-C, TG, and sICAM-1 levels.
- Bezafibrate (Group B) significantly decreased TC, TG, but not LDL-C or sICAM-1.
- Diet (Group D) significantly decreased TC, LDL-C, and TG, but not sICAM-1. Pravastatin's reduction in sICAM-1 was independent of its effects on TC and TG.
Conclusions:
- Pravastatin administration significantly reduced sICAM-1 levels in chronic CVD patients.
- This reduction occurred independently of its effects on total cholesterol and triglycerides.
- Pravastatin may possess distinct anti-atherosclerotic mechanisms beyond lipid modification.
Objective:
We examined the effects of drug therapy with pravastatin (P) or bezafibrate (B) and diet (D) therapy on serum lipids and soluble intercellular adhesion molecule-1 (sICAM-1) in hyperlipidemic cerebrovascular disease (CVD) patients in the chronic stage.
Methods:
This study included 36 patients (28 with cerebral infarction and hyperlipidemia and eight with cerebral hemorrhage and hyperlipidemia) divided into three groups: Group P (12 patients), Group B (10 patients), and Group D (14 patients). Before and after treatment, total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglyceride (TG), high density lipoprotein cholesterol (HDL-C) and sICAM-1 levels were measured.
Results:
In Group P, Group B and Group D, TC levels were decreased by 30% (p < 0.005), 21% (p < 0.01), and 21% (p < 0.001), LDL-C levels were decreased by 38% (p < 0.005), 18% (not significant), and 25% (p < 0.005) and TG levels were decreased by 27% (p < 0.05), 53% (p < 0.005) and 22% (p < 0.05), respectively. sICAM-1 levels were decreased by 20% (p < 0.005) in Group P, but were not decreased in Group B or Group D. There was no correlation between deltaTC and delta sICAM-1 (r = 0.172).
Conclusion:
Administration of pravastatin significantly reduced sICAM-1 levels, independently of its decreasing effect on TC and TG in chronic CVD patients. Pravastatin may exert anti-atherosclerotic activity via two distinct mechanisms.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:23Atherosclerosis IV: Nursing Management